Treating Heparin-lnduced Thrombocytopenia in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation

Jonathan Eisenberger*, Shmuel Somer, Eilon Ram, Eyal Nachum, Jonathan Frogal, Shany Levin, Jacob Lavee, Leonid Sternik, Jeffrey Morgan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Unfractionated heparin is the preferred anticoagulant used during open heart surgeries, including left ventricular assist device (LVAD) implantation. In cases in which patients are heparin-induced thrombocytopenia positive (HIT+), the accepted practice has been to substitute heparin with bivalirudin. This practice may be associated with significant bleeding and adverse outcomes. Objectives: To review our experience with HIT+ patients who were heparin-induced thrombocytopenia with thrombosis negative (HITT-) and who underwent HeartMate 3 LVAD implantation using heparin intraoperatively rather than bivalirudin. Methods: From 2016 to 2022,1 44 adult patients were implanted with HeartMate 3 LVAD at our center. Among them, seven were detected as HIT+ but HITT- and therefore were prescribed intraoperatively with heparin and treated pre- and postoperatively with bivalirudin. We reviewed the preoperative, intraoperative, and postoperative characteristics as well as short-term mortality and the complication rates of these HIT+ patients. Results: The median age of our cohort was 56 years (51-60), 71% were male (n=5), all were INTERMACS Level 1, and most were bridged to transplant (n=6, 86%). The 30-day mortality rate post-implantation was 0%. The average 24-hour chest drain postoperative output was 1502.86 ± 931.34 ml. There were no intraoperative pump thromboses, perioperative thromboses, cerebrovascular accidents, or gastrointestinal bleeding within the first 24 hours postoperative. One patient required a revision due to bleeding. Conclusions: Intraoperative unfractionated heparin may be administered to patients who are HIT+ and HITT- while undergoing LVAD implantation. However, further investigation is required.

Original languageEnglish
Pages (from-to)757-759
Number of pages3
JournalIsrael Medical Association Journal
Issue number11
StatePublished - 2023


  • cardiopulmonary bypass (CPB)
  • heparin-induced thrombocytopenia (HIT)
  • heparin-induced thrombocytopenia with thrombosis (HITT)
  • left ventricular assist device (LVAD)
  • platelet factor 4 (PF4)


Dive into the research topics of 'Treating Heparin-lnduced Thrombocytopenia in Patients Undergoing HeartMate 3 Left Ventricular Assist Device Implantation'. Together they form a unique fingerprint.

Cite this